Importance of Standardized Workflows and Quality Control

Kathryn Collinet

Kathryn Collinet, PhD, is a Technical and Marketing Writer for Personalized Healthcare and Oncology at QIAGEN. She trained as a molecular biologist at the University of Barcelona and the Institute for Research in Biomedicine, where she studied DNA and protein modifications and their influence on chromatin conformation and gene expression. Since 2011 Kathryn has been working in marketing communications for the scientific information and molecular diagnostics industries. Kathryn has a passion for delivering knowledge and insights about molecular and clinical technologies, and their power to impact research and healthcare.

Your email address will not be published. Required fields are marked *

More Articles Like This

PITX2: A novel biomarker to support breast cancer therapy selection

PITX2 DNA methylation status is a clinically relevant biomarker to predict survival in a variety of cancers, including breast cancer, and is a predictive biomarker for treatment response in high- risk breast cancer patients. Applying PITX2 methylation as a predictive biomarker can help avoid use of chemotherapy in patients that would receive  little or no... Read article →

Multi-center study shows QIAGEN’s ipsogen JAK2 MutaQuant Kit is robust, efficient and sensitive for quantitative detection of the JAK2 V617F mutation

A network study of multiple laboratories finds the ipsogen JAK2 MutaQuant Kit to be robust, efficient and sensitive for quantitative detection of the JAK2 V617F mutation. This study sets the basis for the standardization of molecular techniques for JAK2 V617F determination. The JAK2 V617F mutation is an important diagnostic biomarker for Philadelphia (Ph)- negative myeloproliferative... Read article →